← board
CNTN
distress 5/10 · elevated risk$2.07-1%today-73% from 52w high
Revenue
pre-revenue
Liquidity
$42M
Runway
2.0 yrs
Shares 1y
+1406%
Price & events
-31.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.0%
1D
-11.5%
1W
-35.9%
1M
-38.6%
3M
-30.1%
6M
+24.7%
1Y
-44.3%
2Y
—
5Y
-99.8%
All
Overview
- Market Cap
- $144.50M
- Volume
- 31.67K
- 52 Week Range
- $1.17 – $7.71
- Total Shares
- 69.80M
- Float Shares
- 63.50M
- Short %
- 9.17%
- % Held by Insiders
- 17.51%
- % Held by Institutions
- 16.51%
- RVOL
- 0.03x
- Beta
- 1.44
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 7
- 2026-01-26partnershipApproved to operate a Super Validator on Canton Network.SEC 8-K
- 2026-01-20partnershipPricing of $55 million registered offering with Clear Street as sole bookrunnerSEC 8-K
- 2025-11-06partnershipEntered into ATM Sales Agreement for up to $64.9M.SEC 8-K
- 2025-11-06partnershipClosed private placement for approximately $545M to acquire Canton Coin and operate as Super Validator.SEC 8-K
- 2024-11-20withdrawalTerminated non-binding exclusive Letter of Intent to combine with Intract Pharma Ltd.SEC 8-K
- 2024-09-16partnershipINT-023/TH023 · Exclusively licensed global rights (ex-South Korea) to oral anti-TNF alpha monoclonal antibody using Soteria and Phloral delivery platforms.SEC 8-K
- 2024-09-11partnershipTH023/INT-023 · Exclusive global license (ex-South Korea) for oral TNF-α inhibitor infliximab using Intract's Soteria and Phloral platforms; includes upfront, milestones, and royalties.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.